Anti-VEGF Compounds in the Treatment of Neovascular Age Related Macular Degeneration
The DOI matches its Crossref record.
Abstract
Age-related macular degeneration (AMD) is the leading cause of blindness among elderly patients in developed countries. Although the pathogenesis of AMD is still largely unknown, it is now well known that vascular endothelial growth factor (VEGF) plays a pivotal role in the growth of the abnormal blood vessels (i.e. choroidal neovascularization, CNV) which characterizes the “wet form” of this ocular disease. Therefore, inhibiting VEGF has turned out to be a good way of more effectively controlling neovascular AMD. VEGF is a heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Currently two anti-VEGF compounds have been approved by the US Food and Drug Administration (FDA) for the treatment of neovascular AMD: pegaptanib and ranibizumab. Off-label usage of bevacizumab, an anti-VEGF agent similar to ranibizumab, has also become fairly common. The substantial improvement of visual acuity noticed in patients treated with ranibizumab has made this drug the gold standard for AMD therapy. However, as with many new therapies, there are unresolved issues, including safety, cost, and dosing frequency. This review describes in details the properties and efficacy of the three anti-VEGF agents in use in clinical practice. Promising emerging anti-VEGF strategies (VEGF-trap, small interfering RNA, tyrosine kinase inhibitors) which aim to improve outcomes, safety and treatment burden through novel mechanisms of action are also discussed. Keywords: Vascular endothelial growth factor, age related macular degeneration, choroidal neovascularization, ranibizumab, bevacizumab, pegaptanib, VEGD-trap, small interfering RNA, tyrosine kinase inhibitors, heparin-binding glycoprotein, potent angiogenic, mitogenic, endothelial cells, proteoglycans, plasmin, matrix metalloproteinases (MMPs), monocytes, dummy/decoy receptor, tyrosine kinase, signal transduction, choriocapillaris, Pegaptanib Sodium, pegylated oligonucleotide aptamer, visual acuity (VA), Intravitreal Lucentis, Endophthalmitis, retinal haemorrhage, conjunctival haemorrhage, nasopharyngitis, hypertension, bronchitis, VEGF-Trap, Bevasiranib
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications
D’souza, A. A., & Shegokar, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1182485 · Cited by 1,282
“[98] PEGylated RNA aptamer – PEG aptanib sodium and Aptanib have improved stability against enzymatic digestion over respective aptamers.[99] PEGylation of therapeutics prevent breakdown of peptides and proteins by pulmonary peptidase, mainly amino peptidases and serine peptidases and thereby offer enhanced mucus pene…”
BackgroundPEG — A versatile conjugating ligand for drugs and drug delivery systems
Kolate, A., Baradia, D., Patil, S., Vhora, I., Kore, G., & Misra, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.046 · Cited by 648
The neurovascular link in health and disease: molecular mechanisms and therapeutic implications
Quaegebeur, A., Lange, C., & Carmeliet, P. (2011) · Neuron · doi:10.1016/j.neuron.2011.07.013 · Cited by 247
From oxygen to erythropoietin: Relevance of hypoxia for retinal development, health and disease
Caprara, C., & Grimm, C. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.11.003 · Cited by 176
Hypomethylation of the IL17RC Promoter Associates with Age-Related Macular Degeneration
Wei, L., Liu, B., Tuo, J., Shen, D., Chen, P., Li, Z., Liu, X., Ni, J., Dagur, P., Sen, H. N., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.10.013 · Cited by 167
“Currently, nomedical or surgical treatment is available for central geographic atrophy (GA), the ‘‘dry’’ form of advanced AMD; however, antivascular endothelial growth factor (anti-VEGF) drugs such as ranibizumab (Lucentis) and bevacizumab (Avastin) have been used to treat CNV AMD, the ‘‘wet’’ form of advanced AMD (Ca…”
Metadata
- Authors
- Campa, C., & P. Harding, S.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-02-01
- Volume
- 12
- Issue
- 2
- Pages
- 173-181
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W1988252501
- Cited by
- 100
- References
- 0
- FWCI
- 14.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-VEGF Compounds in the Treatment of Neovascular Age Related Macular Degeneration. https://app.cochat.ai/papers/10.2174/138945011794182674
- The paper
- Campa, C., & P. Harding, S. (2011). Anti-VEGF Compounds in the Treatment of Neovascular Age Related Macular Degeneration. Current Drug Targets. https://doi.org/10.2174/138945011794182674
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.